medigraphic.com
ISSN 0185-3325 (Print)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2017, Number 2

<< Back

Salud Mental 2017; 40 (2)

An approach to the new psychoactive drugs phenomenon

Dolengevich-Segal H, Rodríguez-Salgado B, Gómez-Arnau J, Sánchez-Mateos D

Language: English
References: 88
Page: 71-82
PDF size: 395.49 Kb.


ABSTRACT

Background. The new psychoactive drugs (NPD) are those that represent a danger to public health and are not prohibited by conventions on international narcotics. The concept also includes new contexts and new routes of consumption as well as novel ways of distribution, notably Internet. The risks associated with NPD consumption are largely unknown to users and to health care providers. Objective. To integrate the existing evidence regarding the main NPD in terms of description, epidemiology, psychopharmacology, medical complications and psychoactive effects. Method. To review relevant and updated clinical information on NPD obtained from specialized books and indexed scientific journals (PubMed/Medline, Google Scholar, Scopus), as well as official documents edited by international organizations dedicated to the epidemiologic analysis of drug abuse and Internet websites and forums managed by psychoactive substance users. Results. Aspects of clinical and pharmacological interest are described comprehensively, together with epidemiological data and risks associated to the consumption of the most relevant NPD: synthetic cannabinoids, synthetic cathinones, NBOMe series, indoleamines, piperazines, hallucinogenic mushrooms (Psilocybe SP.), synthetic opioids, plant products (khat, kratom, Salvia divinorum, ayahuasca) and dissociative anesthetics. Discussion and conclusion. The emergence of the NPD is a phenomenon on the rise with important consequences for public health. Learning about new trends in drug consumption and its potential risks should be essential for the medical professional. New research is needed in order to understand the phenomenon of the NPD and its pharmacological, clinical and legal implications.


REFERENCES

  1. Ahmad, K., & Aziz, Z. (2012). Mitragyna speciosa use in the northern states of Malaysia: a cross-sectional study. Journal of Ethnopharmacology, 141(1), 446-50. https://doi.org/10.1016/j.jep.2012.03.009

  2. Andreasen, M. F., Telving, R., Rosendal, I., Eg, M. B., Hasselstrøm, J. B., & Andersen, L. V. (2015). A fatal poisoning involving 25C-NBOMe. Forensic Science International, 251, e1-8. https://doi.org/10.1016/j.forsciint.2015.03.012

  3. Araújo, A. M., Carvalho, F., Bastos, M. de L., Guedes de Pinho, P., & Carvalho, M. (2015). The hallucinogenic world of tryptamines: an updated review. Archives of Toxicology, 89(8), 1151–73. https://doi.org/10.1007/s00204-015-1513-x

  4. Araújo, A. M., Valente, M. J., Carvalho, M., Dias da Silva, D., Gaspar, H., Carvalho, F., … Guedes de Pinho, P. (2015). Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of “legal high” packages containing synthetic cathinones. Archives of Toxicology, 89(5), 757–71. https://doi.org/10.1007/s00204-014-1278-7

  5. Arbo, M. D., Melega, S., Stöber, R., Schug, M., Rempel, E., Rahnenführer, J., … Hengstler, J. G. (2016). Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Archives of Toxicology, 90(12), 3045–3060. https://doi.org/10.1007/s00204-016-1665-3

  6. Appendino, G., Minassi, A., & Taglialatela-Scafati, O. (2014). Recreational drug discovery: natural products as lead structures for the synthesis of smart drugs. Natural Product Reports, 31(7), 880–904. https://doi.org/10.1039/c4np00010b

  7. Baumann, M. H., Ayestas, M. A., Partilla, J. S., Sink, J. R., Shulgin, A. T., Daley, P. F., … Cozzi, N. V. (2012). The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology, 37(5), 1192–203. https://doi.org/10.1038/ npp.2011.304

  8. Bersani, F. S., Corazza, O., Albano, G., Valeriani, G., Santacroce, R., Bolzan Mariotti Posocco, F., … Schifano, F. (2014). 25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. BioMed Research International, 2014, 734749. https://doi. org/10.1155/2014/734749

  9. Bileck, A., Ferk, F., Al-Serori, H., Koller, V. J., Muqaku, B., Haslberger, A., … Knasmüller, S. (2016). Impact of a synthetic cannabinoid (CP-47,497-C8) on protein expression in human cells: evidence for induction of inflammation and DNA damage. Archives of Toxicology, 90(6), 1369-82. https://doi.org/10.1007/ s00204-015-1569-7

  10. Boyer, E. W., & Shannon, M. (2005). The serotonin syndrome. The New England Journal of Medicine, 352(11), 1112-20. https://doi.org/10.1056/NEJMra041867

  11. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., … Nutt, D. J. (2016). Psilocybin with psychological support for treatment- resistant depression: an open-label feasibility study. The Lancet. Psychiatry, 3(7), 619–27. https://doi.org/10.1016/S2215-0366(16)30065-7

  12. Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014). Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence, 144, 12-41. https://doi.org/10.1016/j.drugalcdep.2014.08.005

  13. Celofiga, A., Koprivsek, J., & Klavz, J. (2014). Use of synthetic cannabinoids in patients with psychotic disorders: case series. Journal of Dual Diagnosis, 10(3), 168–73. https://doi.org/10.1080/15504263.2014.929364

  14. Coppola, M., & Mondola, R. (2015). AH-7921: a new synthetic opioid of abuse. Drug and Alcohol Review, 34(1), 109-10. https://doi.org/10.1111/dar.12216

  15. Corazza, O., Assi, S., & Schifano, F. (2013). From “Special K” to “Special M”: the evolution of the recreational use of ketamine and methoxetamine. CNS Neuroscience & Therapeutics, 19(6), 454-60. https://doi.org/10.1111/cns.12063

  16. Corazza, O., Assi, S., Simonato, P., Corkery, J., Bersani, F. S., Demetrovics, Z., … Schifano, F. (2013). Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project. Human Psychopharmacology, 28(4), 317–23. https://doi.org/10.1002/hup.2299

  17. Currie, C. L. (2013). Epidemiology of adolescent Salvia divinorum use in Canada. Drug and Alcohol Dependence, 128(1–2), 166–70. https://doi.org/10.1016/j. drugalcdep.2012.08.008

  18. Dargan PI & Wood DM (Eds) (2013). Novel Psychoactive Substances: Classification, Pharmacology and Toxicology. London: Elsevier; 2013.ISBN: 978-0-12- 415816-0.

  19. Davey, Z., Schifano, F., Corazza, O., Deluca, P., & Psychonaut Web Mapping Group. (2012). e-Psychonauts: conducting research in online drug forum communities. Journal of Mental Health (Abingdon, England), 21(4), 386–94. https://doi.org/1 0.3109/09638237.2012.682265

  20. Di Forti, M., Sallis, H., Allegri, F., Trotta, A., Ferraro, L., Stilo, S. A., … Murray, R. M. (2014). Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophrenia Bulletin, 40(6), 1509–17. https://doi.org/10.1093/schbul/sbt181

  21. Dolengevich Segal, H., Gómez-Arnau Ramírez, J., Rodríguez Salgado, B., Rabito Alcón, M. F., & Correas, J. (2014). Panorama actual en el uso de drogas emergentes. Health and Addictions: Salud Y Drogas, 14(1), 47–58. Retrieved from http://dialnet.unirioja.es/servlet/articulo?codigo=4782685&info=resumen& idioma=SPA

  22. Dolengevich Segal, H., Rodríguez Salgado, B., Gómez-Arnau Ramírez, J., Frenzi Rabito Alcón, M., & Correas Lauffer, J. (2014). Uso de sustancias psicoactivas en la era de Internet Psychoactive substance use in the Internet era. Revista de Patología Dual, 1(2). https://doi.org/10.17579/RevPatDual.01.6

  23. Dolengevich Segal H., Gómez-Arnau Ramírez J., Rodríguez Salgado B., & Sánchez- Mateos D. (Eds.) (2015). Nuevas Drogas Psicoactivas. España: Entheos. ISBN:978-84-940824-7-4.

  24. Dolengevich-Segal, H., Rodríguez Salgado, B., Gómez-Arnau Ramírez, J., & Sánchez- Mateos, D. (2015). New Psychoactive Drugs. Adicciones, 27(3), 231–2. DOI: https://doi.org/10.20882/adicciones.709

  25. Dolengevich-Segal, H., Rodríguez-Salgado, B., Gómez-Arnau, J., & Sánchez-Mateos, D. (2016). Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. Case Reports in Psychiatry, 2016, 8379562. https:// doi.org/10.1155/2016/837956

  26. El-Khoury, J., & Sahakian, N. (2015). The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series. Journal of Psychoactive Drugs, 47(4), 286–92. https://doi.org/10.1080/02791072.2015.1 073815

  27. Elliott, S. P., Brandt, S. D., Wallach, J., Morris, H., & Kavanagh, P. V. (2015). First reported fatalities associated with the “research chemical” 2-methoxydiphenidine. Journal of Analytical Toxicology, 39(4), 287–93. https://doi.org/10.1093/ jat/bkv006

  28. Espiard, M.-L., Lecardeur, L., Abadie, P., Halbecq, I., & Dollfus, S. (2005). Hallucinogen persisting perception disorder after psilocybin consumption: a case study. European Psychiatry : The Journal of the Association of European Psychiatrists, 20(5–6), 458–60. https://doi.org/10.1016/j.eurpsy.2005.04.008

  29. European Monitoring Centre for Drugs and Drug Addiction. (2015), New psychoactive substances in Europe. An update from the EU Early Warning System (March 2015), Publications Office of the European Union, Luxembourg. ISBN: 978-92-9168-764-0 doi:10.2810/372415.

  30. Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2008). The behavioral pharmacology of hallucinogens. Biochemical Pharmacology, 75(1), 17–33. https://doi. org/10.1016/j.bcp.2007.07.018

  31. Fattore, L., & Fratta, W. (2011). Beyond THC: The New Generation of Cannabinoid Designer Drugs. Frontiers in Behavioral Neuroscience, 5, 60. https://doi. org/10.3389/fnbeh.2011.00060

  32. Fisar, Z. (2010). Inhibition of monoamine oxidase activity by cannabinoids. Naunyn-Schmiedeberg’s Archives of Pharmacology, 381(6), 563–72. https:// doi.org/10.1007/s00210-010-0517-6

  33. García-Repetto, R., Soria, ML. (2011). Drogas emergentes: una perspectiva médico- legal. Rev Esp Med Legal, 37(2):76-82. http://dx.doi.org/10.1016/S0377- 4732(11)70067-0

  34. Giné, C. V., Espinosa, I. F., & Vilamala, M. V. (2014). New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon? Drug Testing and Analysis, 6(7–8), 819–24. https://doi.org/10.1002/dta.1610

  35. Gómez-Arnau, J., Rodríguez-Salgado, B., Sánchez-Mateos, D., & Dolengevich- Segal, H. (2015). “ FLAKKA ”:Una nueva droga psicoactiva en España. Revista de Patología Dual, 2(4), 6–7. https://doi.org/10.17579/RevPatDual. 02.20

  36. Griffiths, P., Lopez, D., Sedefov, R., Gallegos, A., Hughes, B., Noor, A., & Royuela, L. (2010). Khat use and monitoring drug use in Europe: the current situation and issues for the future. Journal of Ethnopharmacology, 132(3), 578–83. https:// doi.org/10.1016/j.jep.2010.04.046

  37. Gunderson, E. W., Haughey, H. M., Ait-Daoud, N., Joshi, A. S., & Hart, C. L. (2012). “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. The American Journal on Addictions, 21(4), 320–6. https://doi. org/10.1111/j.1521-0391.2012.00240.x

  38. Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99–120. https://doi. org/10.1016/j.bbr.2014.07.016

  39. Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004). Acute psychological and physiological effects of psilocybin in healthy humans: a double- blind, placebo-controlled dose-effect study. Psychopharmacology, 172(2), 145–56. https://doi.org/10.1007/s00213-003-1640-6

  40. Helander, A., Bäckberg, M., & Beck, O. (2014). MT-45, a new psychoactive substance associated with hearing loss and unconsciousness. Clinical Toxicology (Philadelphia, Pa.), 52(8), 901–4. https://doi.org/10.3109/15563650.2014.943908

  41. Helander, A., Beck, O., & Bäckberg, M. (2015). Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. Clinical Toxicology (Philadelphia, Pa.), 53(5), 446–53. https://doi.org/10.3109/15563650. 2015.1033630

  42. Hermanns-Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013). Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction (Abingdon, England), 108(3), 534–44. https://doi. org/10.1111/j.1360-0443.2012.04078.x

  43. Kalix, P., & Braenden, O. (1985). Pharmacological aspects of the chewing of khat leaves. Pharmacological Reviews, 37(2), 149–64. Retrieved from http://www. ncbi.nlm.nih.gov/pubmed/2864707

  44. Kersten, B. P., & McLaughlin, M. E. (2015). Toxicology and management of novel psychoactive drugs. Journal of Pharmacy Practice, 28(1), 50–65. https://doi. org/10.1177/0897190014544814

  45. Kjellgren, A., & Jonsson, K. (2013). Methoxetamine (MXE)--a phenomenological study of experiences induced by a “legal high” from the internet. Journal of Psychoactive Drugs, 45(3), 276–86. https://doi.org/10.1080/02791072.2013.8 03647

  46. Kueppers, V. B., & Cooke, C. T. (2015). 25I-NBOMe related death in Australia: a case report. Forensic Science International, 249, e15-8. https://doi.org/10.1016/j. forsciint.2015.02.010

  47. Kyriakou, C., Marinelli, E., Frati, P., Santurro, A., Afxentiou, M., Zaami, S., & Busardo, F. P. (2015). NBOMe: new potent hallucinogens--pharmacology, analytical methods, toxicities, fatalities: a review. European Review for Medical and Pharmacological Sciences, 19(17), 3270–81. Retrieved from http://www.ncbi.nlm. nih.gov/pubmed/26400534

  48. Law, R., Schier, J., Martin, C., Chang, A., & Wolkin, A. (2015). Increase in reported adverse health effects related to synthetic cannabinoids use – United States. MMWR. 64(22); 618-619

  49. Lawn, W., Barratt, M., Williams, M., Horne, A., & Winstock, A. (2014). The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample. Journal of Psychopharmacology (Oxford, England), 28(8), 780–8. https://doi. org/10.1177/0269881114523866

  50. Ledberg, A. (2015). The interest in eight new psychoactive substances before and after scheduling. Drug and Alcohol Dependence, 152, 73–8. https://doi. org/10.1016/j.drugalcdep.2015.04.020

  51. López-Arnau, R., Martínez-Clemente, J., Pubill, D., Escubedo, E., & Camarasa, J. (2012). Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. British Journal of Pharmacology, 167(2), 407–20. https://doi.org/10.1111/j.1476-5381.2012.01998.x

  52. McElrath, K., & O’Neill, C. (2011). Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. The International Journal on Drug Policy, 22(2), 120–7. https://doi.org/10.1016/j. drugpo.2010.11.001

  53. Observatorio Europeo de las Drogas y las Toxicomanías (2016), Informe Europeo sobre Drogas 2016: Tendencias y novedades, Oficina de Publicaciones de la Unión Europea, Luxemburgo. ISBN: 978-92-9168-869-2 doi:10.2810/7535.

  54. Odenwald, M., Neuner, F., Schauer, M., Elbert, T., Catani, C., Lingenfelder, B., … Rockstroh, B. (2005). Khat use as risk factor for psychotic disorders: a cross-sectional and case-control study in Somalia. BMC Medicine, 3, 5. https:// doi.org/10.1186/1741-7015-3-5

  55. Ott J. (2000). Pharmacotheon. España: Los Libros de la Liebre de Marzo.ISBN: 84- 87403-23-9.

  56. Palamar, J. J., & Acosta, P. (2015). Synthetic cannabinoid use in a nationally representative sample of US high school seniors. Drug and Alcohol Dependence, 149, 194–202. https://doi.org/10.1016/j.drugalcdep.2015.01.044

  57. Poklis, J. L., Devers, K. G., Arbefeville, E. F., Pearson, J. M., Houston, E., & Poklis, A. (2014). Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)- N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Science International, 234, e14-20. https://doi.org/10.1016/j.forsciint.2013.10.015

  58. Riba, J., Valle, M., Urbano, G., Yritia, M., Morte, A., & Barbanoj, M. J. (2003). Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. The Journal of Pharmacology and Experimental Therapeutics, 306(1), 73–83. https://doi.org/10.1124/ jpet.103.049882

  59. Rodríguez Salgado, B., Gómez-Arnau Ramírez, J., Sánchez Mateos, D., & Dolengevich Segal, H. (2016). [Vegetables as new psychoactive drugs: a narrative review]. Medwave, 16(1), e6372. DOI. 10.5867/medwave.2016.01.6372. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/26937890

  60. Santacroce, R., Corazza, O., Martinotti, G., Bersani, F. S., Valeriani, G., & Di Giannantonio, M. (2015). Psyclones: a roller coaster of life? Hidden synthetic cannabinoids and stimulants in apparently harmless products. Human Psychopharmacology, 30(4), 265–71. https://doi.org/10.1002/hup.2410

  61. Schultes, RE., Hofmann, A. (2000). Plantas de los Dioses. México DF: Fondo de Cultura Económica. ISBN: 968-16-6303-9.

  62. Schifano, F., Albanese, A., Fergus, S., Stair, J. L., Deluca, P., Corazza, O., … ReDNet Research Groups. (2011). Mephedrone (4-methylmethcathinone; “meow meow”): chemical, pharmacological and clinical issues. Psychopharmacology, 214(3), 593–602. https://doi.org/10.1007/s00213-010-2070-x

  63. Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015). Novel psychoactive substances of interest for psychiatry. World Psychiatry, 14(1), 15–26. http://doi.org/10.1002/wps.20174.

  64. Schmidt, M. M., Sharma, A., Schifano, F., & Feinmann, C. (2011). “Legal highs” on the net-Evaluation of UK-based Websites, products and product information. Forensic Science International, 206(1–3), 92–7. https://doi.org/10.1016/j. forsciint.2010.06.030

  65. Shulgin, A. (1991). PiHKAL: A Chemical Love Story. California: Transform Press. ISBN 10: 0963009605 ISBN 13: 9780963009609

  66. Shulgin, A. (1997). TiHKAL: The Continuation. California: Transform Press. ISBN 10: 0963009699 ISBN 13: 9780963009692

  67. Siddiqi, S., Verney, C., Dargan, P., & Wood, D. M. (2015). Understanding the availability, prevalence of use, desired effects, acute toxicity and dependence potential of the novel opioid MT-45. Clinical Toxicology (Philadelphia, Pa.), 53(1), 54–9. https://doi.org/10.3109/15563650.2014.983239

  68. Singh, D., Müller, C. P., & Vicknasingam, B. K. (2014). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 139, 132–7. https://doi.org/10.1016/j.drugalcdep. 2014.03.017

  69. Stiefel, K. M., Merrifield, A., & Holcombe, A. O. (2014). The claustrum’s proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Frontiers in Integrative Neuroscience, 8, 20. https://doi.org/10.3389/ fnint.2014.00020

  70. Stolt, A.-C., Schröder, H., Neurath, H., Grecksch, G., Höllt, V., Meyer, M. R., … Becker, A. (2014). Behavioral and neurochemical characterization of kratom (Mitragyna speciosa) extract. Psychopharmacology, 231(1), 13–25. https://doi. org/10.1007/s00213-013-3201-y

  71. Tang, M. H. Y., Ching, C. K., Tsui, M. S. H., Chu, F. K. C., & Mak, T. W. L. (2014). Two cases of severe intoxication associated with analytically confirmed use of the novel psychoactive substances 25B-NBOMe and 25C-NBOMe. Clinical Toxicology (Philadelphia, Pa.), 52(5), 561–5. https://doi.org/10.3109/1556365 0.2014.909932

  72. Thekkemuriyi, D. V, John, S. G., & Pillai, U. (2014). “Krokodil”--a designer drug from across the Atlantic, with serious consequences. The American Journal of Medicine, 127(3), e1-2. https://doi.org/10.1016/j.amjmed.2013.09.030

  73. Tylš, F., Páleníček, T., & Horáček, J. (2014). Psilocybin--summary of knowledge and new perspectives. European Neuropsychopharmacology : The Journal of the European College of Neuropsychopharmacology, 24(3), 342–56. https://doi. org/10.1016/j.euroneuro.2013.12.006

  74. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., & Goda, Y. (2013). URB- 754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Science International, 227(1–3), 21–32. https://doi. org/10.1016/j.forsciint.2012.08.047

  75. Ujváry, I. (2014). Psychoactive natural products: overview of recent developments. Annali dell’Istituto Superiore Di Sanita, 50(1), 12–27. https://doi.org/DOI: 10.4415/ANN_14_01_04

  76. United Nations Office on Drugs and Crime (2013). The challenge of new psychoactive substances. Available at: http://www.unodc.org/documents/scientific/NPS_ 2013_SMART.pdf

  77. Van Hout, M. C., & Hearne, E. (2015). “Word of mouse”: indigenous harm reduction and online consumerism of the synthetic compound methoxphenidine. Journal of Psychoactive Drugs, 47(1), 30–41. https://doi.org/10.1080/02791072.2014. 974002

  78. Vardakou, I., Pistos, C., & Spiliopoulou, C. (2010). Spice drugs as a new trend: mode of action, identification and legislation. Toxicology Letters, 197(3), 157–62. https://doi.org/10.1016/j.toxlet.2010.06.002

  79. Walterscheid, J. P., Phillips, G. T., Lopez, A. E., Gonsoulin, M. L., Chen, H.-H., & Sanchez, L. A. (2014). Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. The American Journal of Forensic Medicine and Pathology, 35(1), 20–5. https://doi.org/10.1097/PAF.0000000000000082

  80. Wabe, N. T. (2011). Chemistry, pharmacology, and toxicology of khat (catha edulis forsk): a review. Addiction & Health, 3(3–4), 137–49. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/24494129

  81. Wilkins, C., & Sweetsur, P. (2013). The impact of the prohibition of benzylpiperazine (BZP) “legal highs” on the prevalence of BZP, new legal highs and other drug use in New Zealand. Drug and Alcohol Dependence, 127(1–3), 72–80. https:// doi.org/10.1016/j.drugalcdep.2012.06.014

  82. Winkelman, M. (2014). Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca. Current Drug Abuse Reviews, 7(2), 101–16. DOI: 10.2174/18744737086661501 07120011

  83. Wood, D. M., Sedefov, R., Cunningham, A., & Dargan, P. I. (2015). Prevalence of use and acute toxicity associated with the use of NBOMe drugs. Clinical Toxicology (Philadelphia, Pa.), 53(2), 85–92. https://doi.org/10.3109/15563650.2 015.1004179

  84. World Health Organization. (2014). Alpha methyltryptamine (AMT). Critical Review. in: WHO Expert Committee on Drug Dependence. Thirty-sixth, WHO Technical Report Series No. 991. Geneva, Suiza. Retrieved from: http://www. who.int/medicines/areas/quality_safety/4_20_EPR_2.pdf?ua=1.

  85. Yip L & Dart CR (2014). Is there something more about synthetic cannabinoids?. Forensic Toxicol,32:340-1. DOI: 10.1007/s11419-013-0224-3

  86. Zawilska, J. B., & Andrzejczak, D. (2015). Next generation of novel psychoactive substances on the horizon - A complex problem to face. Drug and Alcohol Dependence, 157, 1–17. https://doi.org/10.1016/j.drugalcdep.2015.09.030

  87. Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009). Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Deutsches Arzteblatt International, 106(27), 464–7. https://doi.org/10.3238/arztebl.2009.0464

  88. Zuba, D., Sekuła, K., & Buczek, A. (2013). 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. Forensic Science International, 227(1–3), 7–14. https://doi.org/10.1016/j.forsciint.2012.08.027




2020     |     www.medigraphic.com